Journals & Publications

Click here for more information on the ASMIRT/NZIMRT 2025 Event

Click for more information on the oral presentation by our NCIS clinician at the SRS ASM 2025:

Click for more information on the poster presentation by our NCIS clinician at the ICFSR:

Click here for more information on the Asia-Pacific Breast Cancer Summit 2025 Event

Click for more information on the poster and oral presentations by our NCIS clinicians at the American Society of Haematology 2024 Annual Meeting and Exposition:

Click for more information on presentations by our NCIS clinicians at the European Society for Medical Oncology (ESMO) Asia 2024:

Click for more information on the presentation by our NCIS clinician at the Asian Society of Gynecologic Oncology 2024 Meeting:

• Insights on the LARA Trial: Pembrolizumab plus Lenvatinib in Recurrent Clear Cell Gynecological Cancer

Click for more information on the presentation by our NCIS clinician at the Association for the Advancement of Blood & Biotherapies (AABB) 2024:

• Reducing Group and Crossmatch Errors in a Tertiary Academic Hospital in Singapore

Click for more info on presentations received by our NCIS clinicians at the European Society for Medical Oncology (ESMO) Congress 2024:

• Pembrolizumab plus lenvatinib in recurrent clear cell gynecological cancer: Phase II LARA trial (GCGS-OV4/ APGOT-OV3)

Click for more info on awards and presentations received by our NCIS clinician at the World Conference on Lung Cancer 2024:

• IASLC Academy Award

Click for more info on awards and presentations received by our NCIS clinician at the American Society of Clinical Oncology (ASCO) Breakthrough Meeting 2024:

• A phase Ib/II study of pacritinib, an interleukin 1 receptor associated kinase 1 (IRAK1) inhibitor, in patients (pts) with solid tumors harboring the 1q21.3 copy number amplification (CNA)

​​​Click for more info on the presentations:

• Low prevalence of cardiovascular risk factors in persons aged fifty years or younger with venous thromboembolism
• Performance Of Chemiluminescence Assays for Laboratory Diagnosis of Antiphospholipid Syndrome – A Single Centre Experience

​​​Click for more info on the presentations:

• FLAG-IDA + venetoclax (ven) in newly diagnosed (ND) or relapsed/refractory (RR) AML
• Indirect treatment comparisons of daratumumab-pomalidomide-dexamethasone (DPD) and pomalidomide-bortezomib-dexamethasone (PVD) in relapsed/refractory multiple myeloma (RRMM)
• Role of autologous stem cell transplantation in patients with primary CNS lymphoma: real-world data from a retrospective multi-centre analysis

​​​​Click for more info on the poster presentations:

• Multi-ethnic genome-wide association study to identify a novel locus for susceptibility to immunerelated adverse events from immune checkpoint inhibitors
• FLAG-IDA + venetoclax in newly diagnosed (ND) or relapsed/refractory (RR) AML
• A phase 2 study of trifluridine/tipiracil (FTD/TPI) in recurrent/metastatic nasopharyngeal (r/m NPC) carcinomas with or without prior exposure to fluoropyrimidines

​​​​Click for more info on the poster presentations:

• CT160 – A phase I trial to evaluate allogenic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T cells in subjects with advanced solid tumors or haematological malignancies (the ANGELICA trial)

​​​​Click for more info on the poster presentations:

• Total neoadjuvant therapy (TNT) for locally advanced rectal cancer (LARC): Real-world experience from a tertiary Asian cancer center

​​​​Click for more info on the poster presentations:

• Clinical Application of an Ex-Vivo Platform to Guide the Choice of Drug Combinations in Relapsed/Refractory Lymphoma; A Prospective Study
• HLA-Haploidentical Hematopoietic Cell Transplantation of Ex Vivo Tcrαβ-Depleted Grafts with CD45RA-Depleted Memory T Cell Add-Back in Adults and Children with Hematological Malignancies: 4-Year Follow-up of Multicenter Study in Singapore
• Cepp in Previously Untreated Patients with Mature T Cell Lymphomas
• Progression-Free Survival (PFS) According to the Presence of Adverse Cytogenetic Abnormalities in Patients (pts) with Multiple Myeloma (MM) Receiving Ixazomib (ixa)-Based vs Placebo (pbo)-Based Therapy: A Pooled Analysis of the TOURMALINE-MM1, MM2, MM3, and MM4 Phase 3 Studies
• Single Cell Multi-Omic Profiling of Multiple Myeloma with t(4;14) Finds an Immune Microenvironment Gene Signature That Correlates with Clinical Outcomes
• Evaluating Front Line Treatment Regimens for Waldenstrom Macroglobulinaemia: A Systematic Review and Meta-Analysis
• Graft-Vs-Host Disease (GvHD) Prophylaxis with Post-Transplant Cyclophosphamide (PTCy) and Thymoglobulin (ATG) Are More Important Determinants of Cytomegalovirus (CMV) Reactivation after Allogeneic Hematopoietic Cell Transplantation (HCT) Than Ex-Vivo T-Cell Depletion in the Era of Pre-Emptive Therapy
• Lenalidomide Compared to Ixazomib Maintenance in Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis
• Safety, Feasibility and Healthcare Cost Differences between Inpatient and Outpatient Mobilization Chemotherapy for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma: A Single Center Experience

​​​​​Click for more info on the research studies:

• Determinants of response to Daratumumab in Epstein-Barr virus-positive natural killer and T-cell lymphoma
• International consensus guidelines on liver transplantation for non-resectable colorectal liver metastases
• Epigenetic promoter alterations in GI tumour immune-editing and resistance to immune checkpoint inhibition

​​​​​​Click for more info on the poster presentations:

• 515MO A phase I trial of durvalumab (Durv) in combination with olaparib (Ola) and capivasertib (Cap) in patients (pts) with advanced or metastatic cancers (Ca) (MEDIPAC)
• 1699P Introduction of the GOLDEN (Geriatric Oncology LongituDinal End to eNd) programme in a tertiary cancer centre